The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research Grant from Pfizer supports researchers in the USA working on ATTR Amyloidosis. Applicants must be based at a research institution and must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
The grant seeks to fund projects on:
- Approaches for the early identification and follow up of ATTR amyloidosis patients
- Real-world (RW) efficacy and safety of tafamidis in the clinical setting for the management of
- ATTR amyloidosis
- Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy
- and polyneuropathy)
- Gender/sex-related differentiation
Applicants may apply for up to 75,000 USD/year in funding support (including up to 28% of overheads) for 1-2 years.
Applications close on April 27, 2023.